Security key
140755109
Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA)
CUSIP: 140755109
Q4 2022 13F Holders as of 31 Dec 2022
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 33,996,854
- Total 13F value
- $365,121,945
- Share change
- -554,040
- Put/Call ratio
- 55%
- SEC-reported price per share
- $10.74
- Number of holders
- 161
- Value change
- -$4,541,381
- Number of buys
- 77
- Number of sells
- 57
- Shares outstanding
- 54,790,889
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2022
Institutions
161
Top holders
10
CARA full security history
Ownership snapshot
Full 13F holder table
Tvardi Therapeutics, Inc. SEC filings
Tvardi Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of CARA - Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
CSL LTD
Disclosed value leader
BlackRock Finance, Inc.
Comparable rows
0/15
Latest evidence
30 Sep 2022
3/4/5
13F
Highest disclosed value: $70,972,000
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
BlackRock Finance, Inc. has the largest disclosed position value at $70.97M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock Finance, Inc.'s linked filing trail.
Disclosed position value
Top 5
CSL LTD
$9.02M
Vifor (International) Ltd
$9.02M
BlackRock Finance, Inc.
$70.97M
VANGUARD GROUP INC
$30.96M
Bain Capital Life Sciences Invest...
$24.78M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| CSL LTD |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$9,024,059
7,396,770 shares
|
— | 09 Aug 2022 |
| Vifor (International) Ltd |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$9,024,059
7,396,770 shares
|
— | 20 Oct 2021 |
| BlackRock Finance, Inc. |
13F
Company
|
—
denominator unverified
|
$70,972,000
7,582,294 shares
|
— | 30 Sep 2022 |
| VANGUARD GROUP INC |
13F
Company
|
—
denominator unverified
|
$30,962,000
3,307,851 shares
|
— | 30 Sep 2022 |
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
—
denominator unverified
|
$24,780,000
2,647,473 shares
|
— | 30 Sep 2022 |
| FARALLON CAPITAL MANAGEMENT, L.L.C. |
13F
Company
|
—
denominator unverified
|
$23,400,000
2,500,000 shares
|
— | 30 Sep 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
161
Shares
33,996,854
Rows available
161
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2022 vs Q3 2022 Across Filers
Q3 2022 holders
152
Q4 2022 holders
161
Holder diff
9
| Investor | Q3 2022 Shares | Q4 2022 Shares | Share Diff | Share Chg % | Q3 2022 value | Q4 2022 value | Value change | Value Chg % |
|---|